TMCnet News

Study Provides Hope for Millions of Diabetic Wound Sufferers
[May 21, 2015]

Study Provides Hope for Millions of Diabetic Wound Sufferers


EO2 Concepts®, an advanced wound-care technology company, has published interim study results on an innovative new treatment approach that could lead to more effective and less expensive treatment of chronic wounds suffered by millions of diabetics.

The study, a prospective, randomized, multi-center, double-blind clinical trial, suggests encouraging trends for patients receiving Continuous Diffusion of Oxygen (CDO) therapy, both in compatibility or superiority to existing CMS-covered therapies and, in particular, for slower-to-close, larger, chronic wounds. The absolute performance of 53 percent of patients receiving CDO therapy experiencing complete wound closure in 12 weeks compares very favorably to published results from other CMS covered therapies (30-52 percent). In a series of exploratory analyses, significant and beneficial effects were found compared to patients who did not receive CDO therapy.

The data, published in Wound Medicine, suggest that the more CDO therapy is needed (larger, more chronic wounds), the better it works.

"CDO is a very promising therapeutic approach that we believe could transform the current standard of care for chronic wounds," said Mark Niederauer, Ph.D., Chief Operating Officer at EO2 Concepts. "We are greatly encouraged by the interim results. The therapy was found to have results equivalent or superior to other advanced treatments, yet has the advantages of being easier to apply and less expensive. There is so much potential for this appoach to make a real difference to the millions of diabetes victims who struggle with chronic wounds."



In this ongoing study, EO2 Concepts is using its TransCu O2 (News - Alert) tissue oxygenation device to provide oxygen inside moist wound therapy dressings to the wounds of half of the study participants. The other half of the study group also received a TransCu O2 device with moist wound therapy dressings, but no oxygen. Neither the patients nor the treating physicians are aware of whether the patient is receiving oxygen therapy.

The TransCu O2 is a small, simple, easy-to-use oxygen delivery system that is portable and allows for constant treatment without limiting mobility. Its ability to provide a continuous, round-the-clock supply of low-flow pure oxygen can treat a variety of lower limb wound types such as venous leg ulcers, diabetic foot ulcers and pressure ulcers.


While oxygen-based therapies are proven effective in treating chronic wounds, the therapeutic approach to allow for 24-hour delivery of diffused oxygen is relatively new. CDO therapy works by diffusing oxygen directly into a moist wound, providing an optimized environment for the healing process. CDO therapy has been shown to improve healing time and success rates for foot, venous and pressure ulcers, skin grafts and burns, while significantly reducing costs compared to other therapies.

"With our TransCu O2 system, we have a simple solution to get CDO to a wound efficiently and effectively," Niederauer said. "We are currently proceeding with additional studies that we expect to further validate the efficacy of our approach."

Diabetes sufferers are more likely to acquire sores or ulcers on their feet due to limited feeling in limbs, poor blood circulation and a weakened immune system. Wounds left untreated for as little as a week can lead to amputation and a severe detraction from quality of life.

About EO2 Concepts

EO2 Concepts is a privately held, advanced wound care technology company and the developer of a progressive FDA-cleared Class II medical device that provides therapy to difficult-to-heal wounds. The TransCu O2 is an electrochemical tissue oxygenation and wound monitoring system for use with OxySpur™ Oxygen Diffusion Dressings as an adjunctive therapy to treat oxygen compromised wounds. For more information, please visit www.eo2.com.


[ Back To TMCnet.com's Homepage ]